NO20060165L - Anvendelse av prionkonverteringsmodulerende midler - Google Patents

Anvendelse av prionkonverteringsmodulerende midler

Info

Publication number
NO20060165L
NO20060165L NO20060165A NO20060165A NO20060165L NO 20060165 L NO20060165 L NO 20060165L NO 20060165 A NO20060165 A NO 20060165A NO 20060165 A NO20060165 A NO 20060165A NO 20060165 L NO20060165 L NO 20060165L
Authority
NO
Norway
Prior art keywords
modulating agents
apolipoprotein
prion
prion conversion
conversion modulating
Prior art date
Application number
NO20060165A
Other languages
English (en)
Other versions
NO338179B1 (no
Inventor
Claudio Soto-Jara
Kinsey Maundrell
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20060165L publication Critical patent/NO20060165L/no
Publication of NO338179B1 publication Critical patent/NO338179B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Anvendelse av Apolipoprotein B, Apolipoprotein E, fragmenter og hermere derav er tilveiebrakt for diagnose, deteksjon, prognose og terapeutisk anvendelse i prionsykdommer. Mer spesifikt tilveiebringer oppfmnelsen anvendelsen av Apolipoprotein B eller fragmenter derav til å modulere eller identifisere modulatorer av prion proteinreplikasjon som er implisert i patogenesen til overførbar spongioform encefalopati og andre prionsykdommer.
NO20060165A 2003-06-19 2006-01-11 Anvendelse av prionkonverteringsmodulerende midler NO338179B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101795 2003-06-19
PCT/EP2004/051170 WO2004111652A1 (en) 2003-06-19 2004-06-18 Use of prion conversion modulating agents

Publications (2)

Publication Number Publication Date
NO20060165L true NO20060165L (no) 2006-01-11
NO338179B1 NO338179B1 (no) 2016-08-01

Family

ID=33547743

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060165A NO338179B1 (no) 2003-06-19 2006-01-11 Anvendelse av prionkonverteringsmodulerende midler

Country Status (9)

Country Link
US (2) US7598046B2 (no)
EP (1) EP1636592B1 (no)
JP (1) JP5133561B2 (no)
AU (2) AU2004248302B2 (no)
CA (1) CA2525517C (no)
ES (1) ES2401645T3 (no)
IL (1) IL172354A (no)
NO (1) NO338179B1 (no)
WO (1) WO2004111652A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554996B1 (en) * 2007-07-20 2016-04-06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Detection of infectious prion protein by seeded conversion of recombinant prion protein
KR101483438B1 (ko) 2014-04-17 2015-01-16 한림대학교 산학협력단 극미량 병원성 프리온 단백질 검출방법 및 장치
DK3142386T3 (da) * 2015-09-08 2019-07-08 Oticon As Tætningsørestykke
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10434141B2 (en) 2016-05-31 2019-10-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2019071355A1 (en) * 2017-10-13 2019-04-18 Uti Limited Partnership PRODUCTS AND METHODS RELATED TO MULTIPLE SCLEROSIS AS A DISORDER ASSOCIATED WITH MISUSE OF TRANSMISSIBLE PROTEINS
US11446116B2 (en) 2020-07-06 2022-09-20 Perfect Fit Crowns, Llc Method and apparatus for dental crown restorations using prefabricated sleeve-crown pairs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278059A (en) * 1985-12-04 1994-01-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaki Kenkyujo Polypeptide possessing cyclomaltodextrin glucanotransferase activity
US5134121A (en) * 1988-03-28 1992-07-28 Regents Of The University Of California Nerve growth factor peptides
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
TW457240B (en) 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
EP0862460A4 (en) * 1995-10-17 2002-01-02 Univ California METHODS OF REDUCING THE INHIBITION OF APOLIPOPROTEIN E4-INDUCED NEURONAL REMODELING
JPH10239313A (ja) * 1997-02-27 1998-09-11 Dai Ichi Pure Chem Co Ltd ヘパリン親和性物質の測定方法
CA2304505A1 (en) 1997-09-24 1999-04-01 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
US6506880B2 (en) * 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
IL139217A0 (en) 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
US6335610B1 (en) * 2000-06-30 2002-01-01 Ford Global Technologies, Inc. Method and apparatus for determining the operational energy cost of a hybrid vehicle
EE05675B1 (et) 2000-07-07 2013-08-15 Applied Research Systems Ars Holding N.V. Meetod konformse haiguse diagnoosimiseks v?i tuvastamiseks, selleks vajalik katsemenetlus, reaktiivikomplekt ning seade
DE10107083C2 (de) * 2001-02-13 2003-02-20 Abdulgabar Salama Pentosan Polysulfat als Ligand zum Nachweis von Prionen
DE20105791U1 (de) * 2001-04-03 2002-08-14 Mekra Lang Gmbh & Co Kg Spiegelanordnung für Kraftfahrzeuge
JP2002323662A (ja) * 2001-04-24 2002-11-08 Furukawa Electric Co Ltd:The 光フィルタの角度調整装置、角度調整方法及び光モジュール
US20040018554A1 (en) * 2001-05-15 2004-01-29 Green Larry R. Methods and compositions for detection of bovine spongiform encephalopathy and variant creutzfeldt-jacob disease
KR100575944B1 (ko) 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
FR2827047B1 (fr) * 2001-07-03 2003-09-26 Apoh Technollgies Sa Procede de separation et/ou detection et/ou identification et/ou quantification de proteines prions
WO2003045921A1 (en) 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
EP1599173B1 (en) 2002-11-13 2017-02-22 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use

Also Published As

Publication number Publication date
AU2004248302B2 (en) 2009-07-30
NO338179B1 (no) 2016-08-01
US7598046B2 (en) 2009-10-06
US20090317380A1 (en) 2009-12-24
IL172354A (en) 2011-12-29
CA2525517C (en) 2016-05-31
EP1636592B1 (en) 2012-12-19
CA2525517A1 (en) 2004-12-23
US20070020682A1 (en) 2007-01-25
WO2004111652A1 (en) 2004-12-23
ES2401645T3 (es) 2013-04-23
AU2004248302A1 (en) 2004-12-23
JP2007527504A (ja) 2007-09-27
JP5133561B2 (ja) 2013-01-30
EP1636592A1 (en) 2006-03-22
AU2009232094A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
NO20060165L (no) Anvendelse av prionkonverteringsmodulerende midler
Leonardi et al. Ocular surface expression of SARS-CoV-2 receptors
Guerra et al. Hereditary palmoplantar keratodermas. Part I. Non‐syndromic palmoplantar keratodermas: classification, clinical and genetic features
Lappin et al. Influence of periodontal disease, Porphyromonas gingivalis and cigarette smoking on systemic anti‐citrullinated peptide antibody titres
Kim et al. Angioedema deaths in the United States, 1979–2010
DE602004028590D1 (de) Gerät zur wiederherstellung der aortenklappe und dieses verwendende behandlungsverfahren
NO20083044L (no) Deteksjon av loselige adisponektinreseptorpeptider og anvendelse i diagnostikk og terapi
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
CO6260094A2 (es) Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos
BRPI0515079A (pt) marcadores imobilizados e métodos de detecção de prions conformacionalmente alterados
NO20071018L (no) Kombinasjonsbehandling ved a anvende fusjonsproteiner omfattende GLP-1
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
MX2019005415A (es) Anticuerpos de il-6 y uso de los mismos.
Rashid et al. Functional up‐regulation of endopeptidase neurolysin during post‐acute and early recovery phases of experimental stroke in mouse brain
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
EA200601760A1 (ru) Тетрагидроиндазольные модуляторы каннабиноидов
AR062709A1 (es) Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt
BR0312102A (pt) sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
ECSP088786A (es) Tratamientos de las alergias oculares
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
CY1113214T1 (el) Φαρμακευτικη συνθεση
Björk et al. The importance of the second hairpin loop of cystatin C for proteinase binding. Characterization of the interaction of Trp-106 variants of the inhibitor with cysteine proteinases
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS